- All
- Anesthesiology
- Anti-infectives and immunology
- Biologicals
- Blood disorders
- Cardiovascular
- CNS
- Diabetes
- Endocrinology/Sexual health
- Gastrointestinal Diseases
- General modelling
- Lung Diseases
- Methods
- Oncology
- Paediatrics
- Pain
- Peripheral Nervous System
- Safety pharmacology
Admiraal M.M., Velseboer D.C., Tjabbes H., Vis P., Peeters-Scholte C., Horn J.
Neuroprotection after cardiac arrest with 2-iminobiotin: a single center phase IIa study on safety, tolerability, and pharmacokinetics. Frontiers in Neurology 2023. [Link to publication ].
Goulooze S.C, Vis P., Krekels E.H.J., Knibbe C.A.J.
Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses. Expert Review of Clinical Pharmacology 2023 [Link to publication].
Eissing T., Goulooze S.C., Berg van der P., Noort van M., Ruppert M., Snelder N., Garmann D., Lippert J., Heinig R., Brinker M., Heerspink H.J.L.
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD. Diabetes, Obesity and Metabolism 2023 [Link to publication].
Noort van M., Ruppert M., Goulooze S.C., Berg van den P., Snelder N., Heerspink H.J., Garmann D., Lippert J., Heinig R., Brinker M., Eissing T. From glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies. PAGE 2023 [Link to publication]
Richard Hooijmaijers R., Parasrampuria R., Marostica E., Ferron-Brady G., Post T.M., Visser S.A.G. Building an adaptive dose simulation framework to aid dose and schedule selection. CPT: Pharmacometirics & Systems Pharmacology, 2023. [Link to publication].
Collins J., Noort van M., Rathi C., Post T.M., Struemper H., Jewell R.C., FerronBrady G. Longitudinal Efficacy and Safety Modeling and Simulation
Framework to Aid Dose Selection of Belantamab Mafodotin for Patients with Multiple Myelo. CPT Pharmacometrics Syst. Pharmacol. 2023 [Link to publication].
Jensen J.T., Reinecke I., Post T.M. , Lukkari-Lax E. , Hofmann B.M,
Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs. Contraception, 2023. [Link to publication].
Fu Y., Snelder N., Guo T., Graaf van der P.H., Hasselt J.G.C. Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies. Pharmaceutics, 2023 [Link to publication].
Willmann S., Keller A.K., Meyer M., van der Mey D., Wirsching G., Zhang Y., Drenth H., Keunecke A., Vendel E. Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension. Pediatiric Pulmonology, 2022. [Link to publication].
Willmann S., Ince I, Ahsman M., Coboeken K., Zhang Y., Thelen K., Kubitza D., Zannikos P., Zhou W., Pina L., Post T., Lippert J.
Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients with congenital heart disease aged 9 years and above. CPT: pharmacometrics & systems pharmacology, p001-011, 2022. [Link to publication].
Muliaditan M, Sepp A. Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies. Clin Transl Sci. 2022. [Link to publication]
Fu Y., Taghvafard H., Said M.M., Rossman E.I., Collins T.A., Billiald-Desquand S., Leishman D., Graaf van der P.H., Hasselt van C.J.G., Snelder N. A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables. CPT Pharmacometrics Syst Pharmacol. 2022;00:1–13. [Link to publication].
Engbers A.G.J., Völler S., Flint R.B., Goulooze S.C., de Klerk J., Krekels E.H.J., van Dijk M., Willemsen S.P., Reiss I.K.M., Knibbe C.A.J., Simons S.H.P. The Effect of Ibuprofen Exposure and Patient Characteristics on the Closure of the Patent Ductus Arteriosus in Preterm Infants. Clin Pharmacol Ther. 2022 [Link to publication]
Goulooze S.C., Heerspink H.J.L., van Noort M., Snelder N., Brinker M., Lippert J. Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD. T. Clin Pharmacokinet. 2022 [Link to publication].
Bosch R., Petrone M., Arends R., Vicini P., Sijbrands E.J.G., Hoefman S., Snelder N. A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist. CPT Pharmacometrics Syst Pharmacol, 2021. [Link to publication]